Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Gene Rank description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1201 to 1250 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1201\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.107333\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.432185\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248349665\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FAM40A\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1202\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0689331\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.277567\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248347606\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TMTC4\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1203\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0900162\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.362464\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248345215\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FAM40B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1204\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KV CHANNEL INTERACTING PROTEIN 1; VESICLE APC-BINDING PROTEIN; A-TYPE POTASSIUM CHANNEL MODULATORY PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.287166\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.15632\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248344749\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCNIP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1205\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZINC FINGER PROTEIN T86. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.130571\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.525788\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248333929\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ZNF593\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1206\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LYSYL-TRNA SYNTHETASE (EC 6.1.1.6) (LYSINE--TRNA LIGASE) (LYSRS). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.318597\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.28364\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248198093\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KARS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1207\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.110079\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.443579\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248160981\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1208\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNA-BINDING PROTEIN NOVA-1 (NEURO-ONCOLOGICAL VENTRAL ANTIGEN 1) (ONCONEURAL VENTRAL ANTIGEN-1) (PARANEOPLASTIC RI ANTIGEN) (VENTRAL NEURON-SPECIFIC PROTEIN 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.107742\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.434244\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248113964\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NOVA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1209\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DYSTROBREVIN BETA (BETA-DYSTROBREVIN) (DTN-B). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.86712\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.49509\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248096616\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DTNB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1210\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"BETA-2-SYNTROPHIN (59 KDA DYSTROPHIN-ASSOCIATED PROTEIN A1, BASIC COMPONENT 2) (SYNTROPHIN 3) (SNT3) (SYNTROPHIN-LIKE) (SNTL). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0666089\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.26852\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248059362\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNTB2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1211\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ANGIOMOTIN LIKE 2; LEMAN COILED-COIL PROTEIN; ANGIOMOTIN-LIKE PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.064293\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.259184\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248059294\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
AMOTL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1212\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"LIPOAMIDE ACYLTRANSFERASE COMPONENT OF BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX, MITOCHONDRIAL PRECURSOR (EC 2.3.1.-) (E2) (DIHYDROLIPOAMIDE BRANCHED CHAIN TRANSACYLASE) (BCKAD E2 SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.121426\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.489504\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24805926\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DBT\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1213\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DYSTROPHIN. \vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0802494\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.323509\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.24805925\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1214\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ANGIOMOTIN. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
AMOT\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1215\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"BETA-1-SYNTROPHIN (59 KDA DYSTROPHIN-ASSOCIATED PROTEIN A1, BASIC COMPONENT 1) (DAPA1B) (TAX INTERACTION PROTEIN 43) (TIP-43) (SYNTROPHIN 2) (BSYN2). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SNTB1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1216\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NITRILASE 1. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
NIT1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1217\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UTROPHIN (DYSTROPHIN-RELATED PROTEIN 1) (DRP1) (DRP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0621046\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.250362\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24805921\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UTRN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1218\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ALPHA-1-SYNTROPHIN (59 KDA DYSTROPHIN-ASSOCIATED PROTEIN A1, ACIDIC COMPONENT 1) (PRO-TGF-ALPHA CYTOPLASMIC DOMAIN-INTERACTING PROTEIN 1) (TACIP1) (SYNTROPHIN 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0640593\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.258242\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248059185\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNTA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1219\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0424937\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.171305\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248058726\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WDR55\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1220\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PESCADILLO HOMOLOG 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.913889\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.68475\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248019269\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PES1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1221\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VISININ-LIKE PROTEIN 3 (VILIP-3) (CALCIUM-BINDING PROTEIN BDR-1) (HLP2) (HIPPOCALCIN-LIKE PROTEIN 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.179279\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.722847\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248017907\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HPCAL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1222\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DYSTROBREVIN ALPHA (DYSTROBREVIN-ALPHA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.762918\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.07607\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248017113\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DTNA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1223\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DEAD-BOX PROTEIN 4 (VASA HOMOLOG). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0678848\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.273711\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248016338\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDX4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1224\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEURON SPECIFIC CALCIUM-BINDING PROTEIN HIPPOCALCIN (P23K) (CALCIUM- BINDING PROTEIN BDR-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.150518\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.606896\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248012839\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HPCA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1225\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEUROCALCIN DELTA. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.14688\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.592229\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.248012171\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NCALD\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1226\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.12354\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.53144\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247943259\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KIAA0020\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1227\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN C1; MAMMALIAN CHROMATIN REMODELING COMPLEX BRG1-ASSOCIATED FACTOR 155; SWI/SNF COMPLEX 155 KDA SUBUNIT; CHROMATIN REMODELING COMPLEX BAF155 SUBUNIT. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.720529\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.90646\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247906044\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SMARCC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1228\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN M (HNRNP M). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.266011\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.07305\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247901775\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HNRPM\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1229\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARF GTPASE-ACTIVATING PROTEIN GIT2 (G PROTEIN-COUPLED RECEPTOR KINASE- INTERACTOR 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.345758\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.39492\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247869412\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GIT2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1230\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.6803\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.74555\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247782776\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RRP12\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1231\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 31 ISOFORM 1; DEAD/DEXH HELICASE DDX31. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0254237\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.102605\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247782272\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDX31\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1232\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0836052\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.33749\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247726451\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KIAA0859\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1233\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POLYBROMO 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.128218\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.517633\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247700591\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PBRM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1234\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POSSIBLE GLOBAL TRANSCRIPTION ACTIVATOR SNF2L2 (SNF2-ALPHA). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.130458\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.526678\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.247699733\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
SMARCA2\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1235\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POSSIBLE GLOBAL TRANSCRIPTION ACTIVATOR SNF2L4 (SNF2-BETA) (BRG-1 PROTEIN) (MITOTIC GROWTH AND TRANSCRIPTION ACTIVATOR) (BRAHMA PROTEIN HOMOLOG 1). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SMARCA4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1236\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POSSIBLE GLOBAL TRANSCRIPTION ACTIVATOR SNF2L1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.271278\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.09519\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247699486\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SMARCA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1237\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN A5; SUCROSE NONFERMENTING-LIKE 5. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.307072\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.2397\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247698637\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SMARCA5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1238\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TBP-ASSOCIATED FACTOR 172 (TAF-172) (TAF(II)170). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.283008\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.14255\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247698569\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BTAF1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1239\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"POTASSIUM VOLTAGE-GATED CHANNEL, SHAL-RELATED SUBFAMILY, MEMBER 1; SHAL-TYPE POTASSIUM CHANNEL; VOLTAGE-GATED POTASSIUM CHANNEL KV4.1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.280939\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.13458\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247614976\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCND1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1240\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"POTASSIUM VOLTAGE-GATED CHANNEL, SHAL-RELATED SUBFAMILY, MEMBER 3 ISOFORM 1; SHA1-RELATED POTASSIUM CHANNEL KV4.3; VOLTAGE-GATED K+ CHANNEL; POTASSIUM IONIC CHANNEL KV4.3; VOLTAGE-GATED POTASSIUM CHANNEL KV4.3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.307623\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.24236\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247611803\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCND3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1241\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.288556\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.16536\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247611039\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C22orf25\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1242\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYSTATHIONINE GAMMA-LYASE (EC 4.4.1.1) (GAMMA-CYSTATHIONASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0790456\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.319234\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247610217\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CTH\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1243\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"POTASSIUM VOLTAGE-GATED CHANNEL, SHAL-RELATED SUBFAMILY, MEMBER 2; VOLTAGE-SENSITIVE POTASSIUM CHANNEL; VOLTAGE-GATED POTASSIUM CHANNEL KV4.2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.363365\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.46751\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24760649\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCND2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1244\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 2, FACILITATED GLUCOSE TRANSPORTER, MEMBER 6 (GLUCOSE TRANSPORTER TYPE 6) (GLUCOSE TRANSPORTER TYPE 9). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0527752\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.213145\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247602336\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC2A6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1245\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 2, FACILITATED GLUCOSE TRANSPORTER, MEMBER 8 (GLUCOSE TRANSPORTER TYPE 8) (GLUCOSE TRANSPORTER TYPE X1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.069385\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.280228\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247601953\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC2A8\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1246\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA-DIRECTED RNA POLYMERASE II 16 KDA POLYPEPTIDE (EC 2.7.7.6) (RPB4). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.139566\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.563754\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247565427\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
POLR2D\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1247\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FIBRILLARIN (34 KDA NUCLEOLAR SCLERODERMA ANTIGEN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.27878\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5.16557\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247558353\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FBL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1248\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN C2 ISOFORM A; MAMMALIAN CHROMATIN REMODELING COMPLEX BRG1-ASSOCIATED FACTOR 170; CHROMATIN REMODELING COMPLEX BAF170 SUBUNIT; SWI3-LIKE PROTEIN; SWI/SNF COMPLEX 170 KDA SUBUNIT. [Sou\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.66815\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.69939\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247518884\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SMARCC2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1249\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60S ACIDIC RIBOSOMAL PROTEIN P0 (L10E). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.11779\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.476127\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247391977\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RPLP0\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1250\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BLOCK 23. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.11539\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.46643\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.247389748\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/